Baseline characteristic | Polypill-based care n=1569 | Usual care n=1571 |
Age, years (SD) | 62.3 (10.6) | 62.0 (10.9) |
Female, n (%) | 398 (25) | 381 (24) |
BP, mm Hg (SD) | ||
Systolic | 139.2 (20.8) | 139.8 (21.0) |
Diastolic | 79.0 (12.1) | 79.5 (11.9) |
Lipid fractions, mmol/L (SD) | ||
Total cholesterol | 4.2 (1.0) | 4.3 (1.3) |
High-density lipoprotein cholesterol | 1.1 (0.3) | 1.1 (0.3) |
LDL cholesterol (derived) | 2.4 (0.9) | 2.4 (0.9) |
Triglycerides | 1.6 (1.1) | 1.6 (1.0) |
History of symptomatic cardiovascular disease, n (%) | 1192 (76) | 1204 (77) |
Coronary heart disease | 1021 (65) | 1025 (65) |
Cerebrovascular disease | 216 (14) | 231 (15) |
Peripheral vascular disease | 92 (6) | 70 (5) |
Diabetes mellitus, n (%) | 581 (37) | 542 (35) |
Treatment modalities, n (%) | ||
Statin | 1339 (85) | 1333 (85) |
Antiplatelet | 1359 (87) | 1360 (87) |
BP lowering | 1423 (91) | 1429 (91) |
All three | 1193 (76) | 1206 (77) |
Use of all indicated* medications, n (%) | 833 (53) | 880 (56) |
Achievement of European targets treatment targets, n (%) | ||
BP | 762 (49) | 729 (46) |
LDL | 559 (36) | 493 (31) |
Antiplatelet† | 1085 (69) | 1104 (70) |
Physician-intended polypill version prior to randomisation (if patient randomised to polypill), n (%) | ||
Polypill 1‡ | 852 (54) | 866 (55) |
Polypill 2‡ | 717 (46) | 702 (45) |
*Statin, antiplatelet and >2 BP-lowering medications; all were indicated according to the participant’s physician on trial entry.
†Antiplatelet target only applicable to people with established cardiovascular disease.
‡Polypill 1: aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, atenolol 50 mg; polypill 2: aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg.
BP, blood pressure; LDL, low-density lipoprotein; SPACE, Single Pill to Avert Cardiovascular Events.